GlassScriptPhysician profile
Melissa L Ramsden
NPI 1194376228
$922.89
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.90 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $144.71 | 2023 | Amjevita, Enbrel, Otezla |
| Horizon Therapeutics Plc | $124.68 | 2023 | Krystexxa |
| Janssen Biotech, INC. | $113.10 | 2023 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $82.36 | 2023 | Saphnelo |
| Abbvie INC. | $69.44 | 2023 | |
| Janssen Scientific Affairs, LLC | $68.66 | 2023 | Tremfya |
| Radius Health, INC. | $54.41 | 2023 | Tymlos |
| Novartis Pharmaceuticals Corporation | $45.79 | 2023 | |
| Organon LLC | $41.29 | 2023 | Hadlima |
| Sandoz INC. | $40.25 | 2023 | Hyrimoz |
| Ucb, INC. | $35.53 | 2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.75 | 2023 | Cyltezo |
| Aurinia Pharma U.S., INC. | $22.47 | 2023 | Lupkynis |
| Fresenius Kabi USA, LLC | $20.64 | 2023 | Idacio |
| Lilly USA, LLC | $18.24 | 2023 | Taltz |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.57 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Ramsden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.